Status:
COMPLETED
The Prechtl's General Movement Assessment, Hammersmith Infant Neurological Examination and Sensory Profile-2
Lead Sponsor:
Kahramanmaras Sutcu Imam University
Conditions:
Infant Development
Sensory Disorder
Eligibility:
All Genders
25-42 years
Brief Summary
In the Neonatal Intensive Care Unit (NICU), infants encounter many sensory stimuli (excessive noise, bright lights, painful medical applications, etc.) that are not present in the uterus. During the c...
Detailed Description
There are interactions between an individual's neurological thresholds and emotional and behavioral responses or self-regulation strategies. Sensory modulation is an active processing process in which...
Eligibility Criteria
Inclusion
- Term preterm babies with 0-3 months of prenatal, postnatal and natal risk who stayed in the NICU for \>2 weeks for any reason and were corrected after discharge
- Babies with periventricular bleeding, ICH stage 2, 3, 4, cystic PVL, stage 3 HIE, neonatal bilirubin encephalopathy (kernicterius), perinatal stroke, perinatal asphyxia, hydrocephalus
- Babies with chronic lung disease, RDS, BPD and long-term Oxygen support (≥7 days)
- Preterm infants with gram-negative bacteria-associated sepsis, Necrotizing Enterocolitis (NEC), infantile apnea, cerebral malformation
- Preterm babies with low 5th minute Apgar score (3 and below), diagnosed with intrauterine growth retardation, multiple births (twins, triplets), PR
- Infants with prolonged severe hypoglycemia and hypocalcemia
- Surgical conditions such as diaphragmatic hernia or tracheoesophageal fistula
- Babies who are small for gestational age (GYB, less than 3rd percentile) or large for gestational age (GYB, greater than 97th percentile)
- Babies who are MV dependent for more than 24 hours
- Babies born less than 32 weeks of gestation and weighing less than 1500 g
- Healthy term babies
Exclusion
- \- Babies of parents who did not agree to participate in the study/Babies who did not attend follow-up evaluations
- Babies with congenital malformations (Spina Bifida, Congenital Muscular Torticollis, Arthrogryposis Multiplex Congenita)
- Babies diagnosed with metabolic and genetic diseases (Down Syndrome, Spinal Muscular Atrophy, Duchenne Muscular Dystrophy.)
- Babies who are still intubated and dependent on MV at postterm 3 months
- Babies with hearing and vision loss
Key Trial Info
Start Date :
April 15 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 15 2023
Estimated Enrollment :
34 Patients enrolled
Trial Details
Trial ID
NCT05217199
Start Date
April 15 2022
End Date
August 15 2023
Last Update
November 29 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hatice Adıgüzel
Kahramanmaraş, Dulkadiroglu, Turkey (Türkiye), 46100